A promising antioxidant in traumatic brain injury
STUDY: Mîndreanu R et al, Int J Mol Sci 2026;27:3076
STUDY TYPE: Systematic review
FUNDING: Independent
Background
N-acetylcysteine (NAC) converts into the main antioxidant in the brain, glutathione. It is promising but unproven in depression and compulsivity disorders, and may protect the kidneys from lithium toxicity. This study looks at its benefits in neurology.
The Study
They analyzed 23 clinical studies of NAC across seven neurological conditions: six in traumatic brain injury (TBI), five each in Alzheimer’s and Parkinson’s disease, four in multiple sclerosis, two in amyotrophic lateral sclerosis (ALS), and one in migraine. The trials were small and the designs ranged from double-blind randomized controlled trials to open-label single-arm trials.
The strongest signal came from mild TBI, where one double-blind RCT (Hoffer et al.) found that NAC given within 24 hours of blast injury produced complete symptom resolution in 86% of patients by day 7, compared to 42% with placebo — an odds ratio of 3.6. Timing mattered: patients treated after 24 hours showed no benefit.
In Parkinson’s disease, two independent RCTs by Monti et al. found that combined IV and oral NAC improved dopamine transporter binding on DaTscan by 3–8% and modestly improved motor scores (Parkinson’s scale UPDRS). IV NAC also increased brain glutathione concentrations by 55% in PD patients, as measured by 7-Tesla MRS. Oral NAC alone, even at 6000 mg/day, failed to raise brain glutathione — likely due to poor oral bioavailability (estimated at 6–10%).
Trials in the other disorders were inconclusive, showing only trends that didn’t reach statistical significant, positive only on secondary outcomes, or pairing NAC with other treatments that obscured its effects.
In terms of publication bias, seven trials were rated high risk, seven serious, and one critical.
Practice Implications
- NAC is promising for acute traumatic brain injury, and possibly Parkinson’s disease.
- When using over-the-counter NAC, look for products that are tested by independent labs, like those here.
— Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report







